Oramed Pharmaceuticals, Inc.

Mr. Nadav Kidron has served the CEO of Oramed Pharmaceuticals since founding the company in 2006. He is an entrepreneur whose career has included managerial roles in a variety of companies and organizations. Mr. Kidron is a Board Member for Entera Bio. He is also an Advisory Board Member for The Trendlines Group, a group that invests in and develops innovation-based businesses. More Info

Dr. Miriam Kidron was appointed Chief Medical and Technology Officer and director in March 2006. Dr. Kidron is a pharmacologist and a biochemist with a PhD in biochemistry. From 1990 to 2007, Dr. Kidron was a senior researcher in the Diabetes Unit at Hadassah University Hospital in Jerusalem, Israel. During 2003 and 2004, Dr. Kidron served as a consultant to Emisphere Technologies Inc., a company that specializes in developing broad-based proprietary drug delivery platforms. Dr. Kidron was formerly a visiting professor at the Medical School at the University of Toronto (Canada), and is a member of the American, European and Israeli Diabetes Associations. Dr. Kidron is a recipient of the Bern Schlanger Award. More Info

Ms. Yifat Zommer was appointed Chief Financial Officer, Treasurer and Secretary in April 2009. From April 2007 to October 2008, Ms. Zommer served as Chief Financial Officer of Witech Communications Ltd., a subsidiary of IIS Intelligence Information Systems Ltd, a company operating in the field of video transmission using wireless communications. From April 2006 to April 2007, Ms. Zommer acted as Chief Financial Officer for CTWARE Ltd., a telecommunication company. Prior to that she was an audit manager in PricewaterhouseCoopers (PwC), where she served for five years. Ms. Zommer holds a Bachelor of Accounting and Economics degree from the Hebrew University and Business Administration (MBA) from Tel-Aviv University. Ms. Zommer is a certified public accountant in Israel. More Info

Dr. Arbit joined the company in mid-2008, having previously served as the vice president of Medical Research at Emisphere Technologies, where he was a co-inventor of six patents related to drug delivery technology. Previously, Dr. Arbit has held distinguished academic positions as Professor at Cornell University Medical College, Member of the Sloan Kettering Cancer Center (MSKCC) and as Division Director at Memorial Sloan Kettering Cancer Institute in New York. Dr. Arbit has numerous publications in peer reviewed journals and had served on the editorial boards of several medical journals. More Info

Dr. Eldor joined Oramed in 2008 and is the Principal Investigator for all of the company's clinical trials conducted at Hadassah Medical Center. He is an Endocrinologist in the Diabetes unit and Endocrinology Department of Hadassah Medical Center. Dr. Eldor graduated from Hadassah - Hebrew University Medical School. and is currently pursuing post-doctoral work in the Division f Diabetes Unit in the Department of Medicine at the University of Texas, San Antonio. More Info

Professor Amatruda was formerly the Senior Vice President and Franchise Head, Diabetes and Obesity at Merck Research Laboratories. He is board certified in internal medicine, endocrinology and metabolism and has a proven track record in academics and pharmaceutical discovery research and development, including several novel candidate compounds, INDs, translational studies, development programs and four NDAs. More Info

Professor Brazilai is the Director of the Institute for Aging Research at the Albert Einstein College of Medicine. He is a Chaired Professor of Medicine and Molecular Genetics and a member of the Diabetes Research Center, the Divisions of Endocrinology and Geriatrics. He is the Director of the Diabetes Research and Training Center Physiology core, and also the co-Director of the Montefiore Hospital Diabetes Clinic. More Info

Professor Ele Ferrannini has published over 350 original papers and 50 book chapters, and is amongst the "highly cited scientists." (ISIhighlycited.com). One of many great honors achieved by Professor Ferrannini includes being elected a past President to the EASD, European Association for the Study of Diabetes. The Association is based on individual membership and embraces scientists, physicians, laboratory workers, nurses and students from all over the world who are interested in diabetes and related subjects in Europe, such as the ADA, American Diabetes Association does in America. Professor Ferrannini has worked with various institutions including the Department of Internal Medicine, University of Pisa School of Medicine, and CNR (National Research Council) Institute of Clinical Physiology, Pisa, Italy; Diabetes Division, Department of Medicine, University of Texas Health Science Center at San Antonio, Texas, USA. He has also had extensive training focused on microbiology, immunology, endocrinology, and specializing in diabetes studies. More Info

Professor Hershko joined the Oramed Scientific Advisory Board in July 2008. In 2004, he received the Nobel Prize in Chemistry. He earned his M.D. (1965) and PhD (1969) from the Hebrew University - Hadassah Medical School of Jerusalem, a period which included service as a physician in the Israel Defense Forces (1965-67). After a post-doctoral fellowship with Gordon Tomkins at the University of San Francisco (1969-72), he joined the faculty of the Haifa Technion becoming professor in 1980. He is now Distinguished Professor in the Unit of Biochemistry in the B. Rappaport Faculty of Medicine of the Technion. More Info

Professor LeRoith has been a member of Oramed's scientific advisory board since 2006 and is currently the Chief of the Division of Endocrinology, Diabetes and Bone Diseases at Mt. Sinai School of Medicine, NY. He has worked at the NIH since 1979 in the field of Endocrinology and Diabetes and rose to be head of the Diabetes Branch at the National Institutes of Health in Bethesda M.D., a position he held until 2005. More Info

Dr. Michael Berelowitz was appointed as a director on June 1, 2010 and in 2011 also became the Chairman of the Scientific Advisory Board. Dr. Berelowitz is the former Senior Vice President and Head of Clinical Development and Medical Affairs in the Specialty Care Business Unit at Pfizer, Inc. From 1996 to 2009 he served in various roles at Pfizer, Inc., beginning as a Medical Director in the Diabetes Clinical Research team and then assuming positions of increasing responsibility until being appointed to his present role. Prior to that, Dr. Berelowitz spent a number of years in academia. Among his public activities, Dr. Berelowitz has served on the board of directors of the American Diabetes Association, the Clinical Initiatives Committee of the Endocrine Society, and has chaired the Task Force on Research of the New York State Council on Diabetes. He has also served on several editorial boards, including the Journal of Clinical Endocrinology and Metabolism and Endocrinology, Reviews in Endocrine and Metabolic Disorders and Clinical Diabetes. Dr. Berelowitz has authored and co-authored more than 100 peer-reviewed journal articles and book chapters in the areas of pituitary growth hormone regulation, diabetes and metabolic disorders. More Info

Mr. Leonard Sank was appointed as a director in October 2007. Mr. Sank is a South African entrepreneur and business man who is devoted to entrepreneurial endeavors and initiatives. He has over 20 years of experience playing important leadership roles in developing businesses. He was a director in Eastvaal Motor Group, a diversified retail motor business. He was also director in Vecto Finance, a credit lending business. He has also served as a director of Macsteel Service Centres SA Pty Ltd., South Africa’s largest private company. He also serves on the board of local non-profit charity organizations in Cape Town, where he resides. More Info

Dr. Harold Jacob was appointed as a director in July 2008. Since 1998, Dr. Jacob has served as the president of Medical Instrument, a company which provides a range of support and consulting services to start-up and early stage companies as well as patenting its own proprietary medical devices. Dr. Jacob has advised a spectrum of companies in the past and served as a consultant and then as the Director of Medical Affairs at Given Imaging Ltd., during 1997 to 2003, a company that developed the first swallowable wireless pill camera for inspection of the intestine. He has licensed patents to a number of companies including Kimberly Clark Ballard. Since 2003, Dr. Jacob has served as the CEO of NanoVibronix, a medical device company using surface acoustics to prevent catheter acquired infection as well as other applications. He practiced clinical gastroenterology in New York and served as Chief of Gastroenterology at St. Johns Episcopal Hospital and South Nassau Communities Hospital in 1986-1995, and was a Clinical Assistant Professor of Medicine at SUNY during 1983-1990. Dr. Jacob founded and served as Editor in Chief of Endoscopy Review and has authored numerous publications in the field of gastroenterology. More Info